DBV Technologies submitted a Biologics License Application to the FDA for the peanut patch in children aged 4-7, supported by Phase 3 data. This regulatory milestone marks progress toward a commercial launch for the food allergy treatment.
DBV Technologies submitted a Biologics License Application to the FDA for the peanut patch in children aged 4-7, supported by Phase 3 data. This regulatory milestone marks progress toward a commercial launch for the food allergy treatment.